Home›Companies›Biotech & Pharma›Holobiome

Holobiome, Inc.

Develops gut bacteria-based therapies and consumer health products for people.

Updated Nov 10, 2026·Latest SEC filing Jul 22, 2026·Suggest an edit

About Holobiome

Holobiome is a private company based in Boston, Massachusetts. It has reported $17,515,554 raised in four offerings on Form D since December 2018. Its chief executive is Philip Strandwitz.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Dec 24, 2025Jul 22, 2026$10,000,000fully sold5$2.0MSimple Agreement for Future Equity (SAFES)Rule 506(b)Form D ↗
Mar 14, 2024Mar 20, 2024$6,590,554of $9.3M target19$346KEquityRule 506(b)Form D ↗
Feb 1, 2021Feb 11, 2021$300,000of $2.0M target2$150KDebtRule 506(b)Form D ↗
Dec 17, 2018Dec 28, 2018$625,000of $1.2M target1$625KDebtRule 506(b)Form D ↗
Total, four offerings$17,515,554

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Holobiome's Form D filed Jul 22, 2026.

Philip Strandwitz
Philip Strandwitz
Co-founder & Director; Chief Executive Officer
ML
Michael LaFleur
Executive officer

Earlier filings also listed Kim Lewis (director, last listed Feb 2021) and Ian Chessell (director, last listed Feb 2021).

Sources

  1. SECHolobiome, Inc. filing history
  2. CompanyHolobiome team
  3. PressHolobiome seed round announcement